|
JULY 5th, 2005
Isolagen, Inc. (AMEX:ILE), a company focused on the development
and commercialization of autologous cellular therapies for soft and hard tissue regeneration, announced positive results for
its Phase II dental study for the treatment of interdental papillary insufficiency. Dr. Michael McGuire, Past President of
the American Academy of Periodontology and a clinical researcher in tissue engineering stated, "The results are very encouraging.
The Isolagen Process appears to offer the potential to grow gum tissue which is something that no other product or treatment
has ever been shown to do before."
Dr. Lindner, Senior Vice President of Medical and Business Affairs,
also commented on the positive results, "Based on these positive results, the company and its clinical experts expect to prepare
protocols for Phase III Pivotal trials to assess the efficacy and safety of our dental product candidate for the treatment
of interdental papillary insufficiency. These clinical trials will be traditional double blind, internal and placebo controlled
studies and will be designed to assess the therapeutic efficacy and safety of our dental product candidate as an aesthetic
product for improving the appearance of gum tissue.”
The company,however, indicated that although the Investigator determined
that the results were superior to the placebo, the linear measurements did not provide statistically significant data. This,
however, was attributed to a lack of accuracy with the measurement instrument. The company plans to investigate other forms
of measurement.
Autologous cellular therapy, according to the company, uses a patient’s
own cells, multiplies them, and then injects them back into the patient.
MAY 17th, 2005
DENTSPLY International Inc. (NASDAQ:XRAY) and Two Cells Co. Ltd.
have entered into an agreement to develop a regeneration therapy based on neurotrophin (BDNF) for the treatment of periodontal
disease. The agreement revolves around a worldwide license from Two Cells and Professor Hidemi Kurihara at the University
of Hiroshima. DENTSPLY as part of the agreement will provide funding for Two Cells.
Mr. Gary Kunkle, DENTSPLY's CEO pointed out that the patent is fundamental
to the agreement, "This license agreement is based on an international patent application titled 'Remedy and Therapeutic Method
for Periodontal Diseases and Pulpal Diseases' submitted by Professor Hidemi Kurihara of Hiroshima University and the University's
venture company, Two Cells Co. Ltd. To date, this applied research into periodontal therapy using BDNF is unprecedented worldwide
and its potential application in periodontal regeneration therapy would provide a significant improvement in the treatment
of this disease."
|
